# Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct07710885/  
OnCo record `nct07710885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin in biliary tract cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.

## Summary

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT07710885 by Taiho Pharmaceutical Co., Ltd., with 784 participants planned, started 2026-06-24 and due to reach its primary completion in 2030-04-30. Interventions recorded: Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07710885
- Phase: 3
- Setting: A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
- Sponsor: Taiho Pharmaceutical Co., Ltd.
- Enrolled: 784

## Sources

- ClinicalTrials.gov NCT07710885: https://clinicaltrials.gov/study/NCT07710885

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct07710885.json